Peptide therapy TikTok claims: what the science actually supports

What did @realalejandroreyes actually say?

The creator is talking about IGF-1, which they mispronounce as "IJF1" throughout. The core claim is that IGF-1 is "one of the strongest peptides you can take" and operates like a gentler, more subtle version of testosterone, producing muscle fullness, better recovery, improved sleep, and stronger connective tissue. They also recommend running it "four to six weeks and then take a break" and offer personalized peptide guidance in DMs. That last part is a red flag we'll get to.

One immediate problem: they never clarify whether they mean endogenous IGF-1, recombinant IGF-1 (mecasermin), or a secretagogue that raises IGF-1 levels indirectly, like a growth hormone-releasing peptide or MK-677. That distinction matters enormously for both the science and the legal and safety picture. Vague peptide content that skips the mechanism is a pattern worth scrutinizing.

Does the science back this up?

Partially, and with significant caveats. IGF-1 does play a real role in muscle protein synthesis and tissue repair, but the creator's framing dramatically oversimplifies how it works and ignores its risk profile.

IGF-1 is primarily produced in the liver in response to growth hormone signaling, and it does mediate much of GH's anabolic effect on skeletal muscle. Yarasheski et al. (1992, American Journal of Physiology) demonstrated that GH administration increases muscle protein synthesis partly through IGF-1 elevation. So the claim that IGF-1 "works with growth hormone signals to actually build muscle tissue" is a reasonable simplification.

On connective tissue, there is some evidence. Doessing et al. (2010, Journal of Physiology) found that local IGF-1 isoforms influence tendon collagen synthesis, lending some support to the claim that connective tissue "feels stronger." However, subjective experience of feeling stronger is not the same as demonstrated structural repair, and the creator blurs that line repeatedly.

Sleep improvement from IGF-1 manipulation is less well-supported in direct research. Any sleep benefit is likely indirect, through GH pulse amplification. Claiming it as a reliable IGF-1 effect is a stretch.

What did they get wrong (or right)?

They got the basic mechanism directionally correct. IGF-1 is anabolic, it does interact with the GH axis, and it does have some role in tissue repair. Credit where it's due.

But they got several things wrong or misleading. First, comparing IGF-1 to testosterone as a "nanny version" implies equivalent physiological territory with softer side effects. That framing is problematic. IGF-1 has its own risk profile, including hypoglycemia, potential promotion of existing neoplastic tissue, and joint pain at higher levels. It is not simply a mild testosterone substitute. Firth and Baxter (2002, New England Journal of Medicine) noted IGF-1's association with cancer risk in epidemiological data, a fact conspicuously absent from this content.

Second, the advice to "run it for four to six weeks and then take a break" is presented as settled guidance with no acknowledgment of individual variation, underlying health status, or the need for clinical supervision. Offering cycle length recommendations to a general social media audience without those qualifications is irresponsible, regardless of how casually it's framed.

Third, offering to send followers personalized peptide guidance via DMs is not clinical care. It is unregulated advice delivered outside any framework that protects the recipient.

What should you actually know?

IGF-1 is a legitimate subject of medical research, but it is not a supplement you self-administer based on TikTok DMs. Here is what the evidence actually supports, and where the gaps are.

• IGF-1 does mediate anabolic signaling downstream of growth hormone, and its role in muscle and connective tissue physiology is well-documented in research settings.
• Exogenous IGF-1 use in healthy adults is not an approved therapeutic application in the United States. Mecasermin (Increlex) is approved only for severe primary IGF-1 deficiency in children.
• Epidemiological studies, including Chan et al. (1998, Science), have linked elevated circulating IGF-1 to increased prostate cancer risk, which is the kind of context that should accompany any enthusiasm about "optimizing" IGF-1.
• The hypoglycemia risk with exogenous IGF-1 is real and acute. This is not a minor footnote.
• If you are interested in peptide therapy for recovery or body composition, that conversation belongs with a licensed clinician who can order labs and monitor your response, not with a social media creator's DM inbox.

The bottom line

This video is not entirely wrong, but it is confidently incomplete in ways that matter. The creator correctly identifies IGF-1 as anabolically active and connected to the GH axis. They are wrong to present it as a low-risk, experiment-friendly compound and wrong to position themselves as a qualified source of personalized peptide guidance. Curiosity about peptides is reasonable. Getting your protocol from TikTok DMs is not.